Table 2.

Pharmacokinetic parameters of mPEG-PCL nanoparticle after intravenous injection of a single dose of mPEG-PCL nanoparticles in rats obtained by fitting to a two-compartmental model^a.

Parameter	PCL-80 nm	mPEG5k-9%-80 nm	mPEG5k-17%-80 nm	mPEG5k-29%-80 nm	mPEG2k-29%-80 nm	mPEG5k-29%-200 nm
t1/2α (h)	0.19 ± 0.10	0.24 ± 0.06	0.20 ± 0.10	0.3 ± 0.14	0.22 ± 0.04	0.27 ± 0.08
t1/2β (h)	15.29 ± 11.19	14.66 ± 2.44	12.58 ± 10.21	5.48 ± 1.21	5.4 ± 1.73	9.72 ± 3.79
K10 (L/h)	0.69 ± 0.44	0.38 ± 0.02	0.66 ± 0.41	0.55 ± 0.1	0.65 ± 0.09	0.45 ± 0.18
K12 (L/h)	3.44 ± 1.95	2.37 ± 0.71	2.83 ± 1.09	1.62 ± 0.66	2.06 ± 0.34	1.88 ± 0.43
K21 (L/h)	0.51 ± 0.47	0.34 ± 0.07	0.83 ± 0.99	0.58 ± 0.22	0.62 ± 0.19	0.41 ± 0.11
AUC0‒t (%·h)	147.02 ± 6.76	193.55 ± 3.28	181.93 ± 2.29	224.63 ± 11.76	166.28 ± 9.56	164.29 ± 8.07
MRT (h)	14.09 ± 0.53	14.55 ± 0.58	14.08 ± 0.52	12.95 ± 0.04	13.15 ± 0.35	14.03 ± 0.36

^aData are presented as mean ± SD (n = 3).